← Eichor
Study identifier: NCT07303699 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)

Condition: Pulmonary Tuberculosis (TB)  ·  Sponsor: Obafemi Awolowo University Teaching Hospital

PhasePhase 2
Planned participants80
Who can joinAll sexes, 12 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to assess pharmacokinetic parameters of atorvastatin at different doses when combined with the standard first line tuberculosis (TB) treatment regimen in adults with drug sensitive pulmonary TB. The pharmacokinetics parameters will be correlated with Pharmcodynamic measures and a PK/PD model that will identify an optimal dosing regimen of atorvastatin that is appropriate for the treatment of pulmonary tuberculosis will be developed.

This description comes directly from the study's public registry record.

Talk to the study team

Olanisun O Adewole, MD  ·  +2348034074930  ·  adewolef@yahoo.co.uk , ola.adewole@oauife.edu.ng

Always discuss trial participation with your own doctor first.

Locations (3)

National Tuberculosis and Leprosy Training Centre, SayeZaria, Kaduna State, NigeriaRecruiting
Federal Teaching HospitalKatsina, Katsina State, NigeriaRecruiting
Obafemi Awolowo University Teaching Hospitals Complex, Ile Ife, Osun state, NigeriaIle-Ife, Osun State, NigeriaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07303699